A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Jung-Yun LeeMyong Cheol LimJae Kwan LeeDae Hoon JeongSe Ik KimMin Chul ChoiByoung Gie KimJung-Yun LeePublished in: Journal of gynecologic oncology (2021)
ClinicalTrials.gov Identifier: NCT04734665.
Keyphrases
- phase ii study
- open label
- phase iii
- locally advanced
- phase ii
- study protocol
- palliative care
- clinical trial
- dna damage
- placebo controlled
- dna repair
- endometrial cancer
- metastatic colorectal cancer
- randomized controlled trial
- squamous cell carcinoma
- radiation therapy
- rectal cancer
- mesenchymal stem cells
- oxidative stress
- double blind
- newly diagnosed